Clinical Trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-24; most recent amendment 2026-05-20.
Trial Details
NCT Number NCT05800587
Lead Sponsor Fox Chase Cancer Center
Conditions Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Enrollment 280 participants
Start Date 2023-02-22
Primary Completion 2028-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-22